Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension

Lu Long, Mark L. Ormiston, Xudong Yang, Mark Southwood, Stefan Gräf, Rajiv D. Machado, Matthias Mueller, Bernd Kinzel, Lai Ming Yung, Janine M. Wilkinson, Stephen D. Moore, Kylie M. Drake, Micheala A. Aldred, Paul B. Yu, Paul D. Upton, Nicholas W. Morrell

Research output: Contribution to journalArticlepeer-review

361 Citations (Scopus)

Abstract

Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. Here, we identify BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH who bear mutations in the gene encoding BMPR-II, BMPR2. Mice bearing a heterozygous knock-in allele of a human BMPR2 mutation, R899X, which we generated as an animal model of PAH caused by BMPR-II deficiency, spontaneously developed PAH. Administration of BMP9 reversed established PAH in these mice, as well as in two other experimental PAH models, in which PAH develops in response to either monocrotaline or VEGF receptor inhibition combined with chronic hypoxia. These results demonstrate the promise of direct enhancement of endothelial BMP signaling as a new therapeutic strategy for PAH.
Original languageEnglish
Pages (from-to)777-785
Number of pages9
JournalNature Medicine
Volume21
Issue number7
DOIs
Publication statusPublished - 15 Jun 2015

Cite this